Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes

Geeta G. Sharma(University of Milano-Bicocca), Roberto Chiarle(Boston Children's Hospital)

Cancers

February 28, 2018

10.3390/cancers10030062

Cited by 97

Related Papers

NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors

|Blood|2003|247

Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells

|Nature|2017|123

Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma

|Blood|2021|48

Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1

|Oncotarget|2016|45

ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer

|Nature Cancer|2023|41